{"name":"Autolus Limited","slug":"autolus-limited","ticker":"","exchange":"","domain":"autoluslimited.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQbHBwT2dTODNESXBIZnRYX09VdUJaeWFBdXVuY2hSSDZIMkY0QzdjQ2VkT0Z6dktjNXNPTTFWbUN6QXBhOHNoeEw0cGhKWGpMTjhaS1ZIaWNWYy16a25XdGkwZ3FvQThwb241OG9BRVQweEF6SERvb0d2YUVvYWpDdVZTY3UtNTNUOGp1cXJmTlVNSTJWTzhZX3BfMzg4UQ?oc=5","date":"2026-03-04","type":"pipeline","source":"BioPharma Dive","summary":"Blackstone puts $400M into Teva, Sanofi gut disease drug - BioPharma Dive","headline":"Blackstone puts $400M into Teva, Sanofi gut disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-13","type":"trial","source":"simplywall.st","summary":"Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials - simplywall.st","headline":"Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQR2FkZXM2MHZuWHJ1b2hub1RSQzVPWEpmdkJkWjgzQXFtYnI5VFNBR1pUNnhJY3hMWkg1eGthZW02T1NBLVpVWEIzd0J6WGdIQnZNWHpMZy11ZV9lMC11RWVQN3R2b0RjelJrWkhIQ002dklMcXhob3VZdlJlWWdZa2lySHlSRlZ1MjVzaEhlT1VITVVGdldEUkdnYnpBQzRuTDdnd0FzcksyWVNuTlJ0aUpaZDlUSEtGSjBGMV9TSHIyZS1DcktpaHNmT2JIR3JzVEN5TkVaOHE3bVhScmZQLWoyYlh1OXBPSVFZX0VSOG52RmYxVHFrSFB5OGdjNWVmbVdaajVqYmtraDdIRUx0NHB3?oc=5","date":"2025-12-29","type":"pipeline","source":"Benzinga","summary":"Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Mon - Benzinga","headline":"Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Mon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE50Z1ZfUjNNenI4R0t1VzZwaFE1QXo3UXBsMkE2bGN0b2Y0ajNIb2U1REhfTnVaYWgwTHNtTTJmM0U4WmxxZUZMTEwyVVh6LWVZV1VybEx3NHQ5R1p3bkRDRU52dE1zaGR1RVA1ZTd3SGx6TG9kV3k3LWJ3MDk?oc=5","date":"2025-11-25","type":"pipeline","source":"pharmaphorum","summary":"NICE backs NHS use of Autolus' leukaemia CAR-T - pharmaphorum","headline":"NICE backs NHS use of Autolus' leukaemia CAR-T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQR2pwNFhFX25iemVTWTVoaTMwRGdIR1pwYTh2MHYxWF8wNFU4ZlBxYzg2eWROYlpwZVA0Q0ZnZkx4Y3kxM3MxeGlfeWFHWlRKbmkwSlpTNUVBRzRiVWF1WmgzamtRZHZSa1ZiNDJFem4xR3I1RGdaaGNzYmFPWjc0cEExSG5VR1hodm5jTDRIWk9YUTZBSEVCV0lSZF9kMkJpbzROY0NaYw?oc=5","date":"2025-11-25","type":"pipeline","source":"Pharmaceutical Technology","summary":"UK-developed leukaemia cell therapy to be offered on NHS - Pharmaceutical Technology","headline":"UK-developed leukaemia cell therapy to be offered on NHS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxONUcyZkZtLVFSSWFpdGhncGlEYXF3OVZNV0lrMzB0M1dKNlhQUHFuLXZfT1V4NGdMSnV0UC1VektMVFA0SV8wQmd1LWxFTDZlZ2FlWlVHY3hYdjlEbEtIM3ctX2NqbHdkaTBpYnUwODdVTjNPR0xjeTFjTnZZejhVMHVnQ3JRcEoyS3lOSUtlcFBhRGc?oc=5","date":"2025-11-06","type":"pipeline","source":"Insightace Analytic","summary":"Immuno-Oncology Cell Therapy Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Immuno-Oncology Cell Therapy Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFRWdk1faWotclNmbkphcC1XeHJ0R0s0UnkyYnF6LVBrQjEycDZJSERQZnk4ZktwUTBHbG1wVTFSU1FxOHVTWUx3WTFnd2I3VlpnWDVEbUVEU05NN29zWlA3ZkFkMWU3YmotRno2S29NdUhWRTJadnc3SzFacVhnTjRwODJENnZXYVh4QzYxSjIwMG4zMnNjaG94VXdRellLZW5PbkpwTnY5RGl3VTlpUW5jYmtDb09iTTg5RHQ0ZG9tTDl0Zk1GQV9nS1R5WUxsOXpkeWtRcURYVEJvQ0dmNnZZSXlYUnBobk1PYw?oc=5","date":"2025-10-06","type":"pipeline","source":"prnewswire.com","summary":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - prnewswire.com","headline":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNdGJiX1hIRnBfajZ4OUVpTXN3X1RHTUNnT1RLdUFOSGlGbHN5NjVnbll1a1h4UEVpNjNHcURnUF9xb1pVM2pwX2JVVFlnWHh6SU9LOFh3U0Zwd1FXZmxpVXpvbHZtcGRhTU14YmxudmF3azRzckJlYUpvZ2dlN2NJbTFPYkdIaTFLVHhOTTZBZWRSNlB5LTQ5UnJOeHlGeUpaVTkwNERUYi02blpuUHhPdjhBZ3p6NTRLTlNLdFZ5Slh6YVlCblhXTGdzYjNEMHMwY0ZwZDV0MDBoU3p5V1RQTnpHb1I1NUJmTGotckNWZzQwSFdTVUdYaFc4S29yWWc5Q1pnTTZib1VxLTRHSmUzbUprc0c1OEdpN2JtZzd1MUxLMm1SNDhjMERR?oc=5","date":"2025-07-07","type":"trial","source":"GlobeNewswire","summary":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum: - GlobeNewswire","headline":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPMDRROGt4MnUwRE1sNnRJZVBYXzZDOWtWc2xsNnVqR1RpWlZyZEVNRG90bHR4cmFzd3AtdnpPa2lud2xsdjdBSjhjNHVPNFRIT1lORDU4NEdYajZsdEx1Wk5jT3dZcV81a1F2Q2dCVG9RNUl3N0w3VF9TZDVENzVjaHY3ZmllRVNiOXNYQnhqcEVmX2dXeGpqdWk2cnNBWFdwbUczV1RSXzZlbzg2c1ByWDlB?oc=5","date":"2025-06-27","type":"regulatory","source":"Fierce Pharma","summary":"FDA removes CAR-T access barriers in move set to boost cancer immunotherapy uptake - Fierce Pharma","headline":"FDA removes CAR-T access barriers in move set to boost cancer immunotherapy uptake","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNbkVpZkIzWHJ0RnB0T1pEbGRtM2VnTmFtVXI0X21EcU1pcWtXbTc1TjlzNVo3WXRQT2pKTTR1Q1RPSkFIcW9FSUNHcmIyZklFVHhTZ01maGRhbTl3dTJaYnZvU3NjT3cxaGRMQ2ZVQWFscFhrbWhfYVBaa29FN0xqR2tzQmc?oc=5","date":"2025-04-28","type":"pipeline","source":"The Pharma Letter","summary":"MHRA backs Aucatzyl for lymphoblastic leukemia - The Pharma Letter","headline":"MHRA backs Aucatzyl for lymphoblastic leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMGZhdGVFeW1IY0RvQnpiVk50MEpCRlEwbGFNd2FTWGE0UkpRLTM3N296Q09sN0dNRjFLanBGNk42TC1Sc3hfVXV3N2ZvSlpvdHhydmpIZ0xuUF8xUG92WE0wQWQyUG1zSU5USUNNTkduV182TC1ZZFhvR2d5VUNnaTJqSnJiUnl2ZE04Z1ozWkpXOW5HRjRPaTdIeURfX2ZiU1h6bEplSlc?oc=5","date":"2025-03-20","type":"pipeline","source":"Fierce Biotech","summary":"BioNTech passes on Autolus' CD19/CD22 CAR-T amid pipeline prioritization - Fierce Biotech","headline":"BioNTech passes on Autolus' CD19/CD22 CAR-T amid pipeline prioritization","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}